跳至主要内容
临床试验/NCT00049777
NCT00049777已完成4 期

A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Heparin in Patients With Severe Sepsis and Higher Disease Severity Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

Eli Lilly and Company1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2002年12月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
2,000
试验地点
1
主要终点
Demonstrate in adult patients with severe sepsis who are receiving drotrecogin alfa (activated) that concomitant treatment with heparin is equivalent to treatment with placebo as determined by 28-day all-cause mortality.

研究概览

简要总结

The purpose of this study is to evaluate the relative efficacy and safety of prophylactic heparin co-administration during drotrecogin alfa (activated) infusion in the treatment of severe sepsis in the adult.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Demonstrate in adult patients with severe sepsis who are receiving drotrecogin alfa (activated) that concomitant treatment with heparin is equivalent to treatment with placebo as determined by 28-day all-cause mortality.

次要结局

  • Determine the incidence of venous thrombotic events in patients receiving heparin vs. placebo through study days 6
  • and 28. Evaluate the safety profile of drotrecogin alfa (activated) and prophylactic heparin co administration by the incidence of intracranial hemorrhage and other serious bleeding events through study day 28.

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

A Trial of Heparin in Patients With Severe Sepsis... | 临床试验